EHA Expert Interview | Prof. Jian Hou Uncovers a New Mechanism of Drug Resistance in Multiple Myeloma Involving eccANKRD28

EHA Expert Interview | Prof. Jian Hou Uncovers a New Mechanism of Drug Resistance in Multiple Myeloma Involving eccANKRD28

The 30th Congress of the European Hematology Association (EHA 2025) was held from June 12 to 15 in Milan, Italy. As one of the world’s leading hematology meetings, this year’s event spotlighted the latest advances across hematologic subspecialties, featuring cutting-edge approaches in diagnosis and treatment, along with new findings in both clinical and translational research. Among the studies presented, a research project led by Professor Jian Hou from Renji Hospital, Shanghai Jiao Tong University School of Medicine, was selected for an oral presentation (Abstract S188). This study sheds light on the critical role of non-coding enhancer-type extrachromosomal circular DNA (eccDNA), specifically eccANKRD28, in the development of drug resistance in multiple myeloma (MM). Oncology Frontier – Hematology Frontier spoke with Prof. Hou onsite for an in-depth discussion of this work.
Dr. Jun Cao: Enhancing Quality of Life in HR⁺ Breast Cancer—Entinostat Offers Patients a Path Back to Normalcy

Dr. Jun Cao: Enhancing Quality of Life in HR⁺ Breast Cancer—Entinostat Offers Patients a Path Back to Normalcy

As treatment options for hormone receptor-positive (HR⁺) breast cancer continue to diversify—from chemotherapy and endocrine therapy to targeted treatments—survival outcomes are improving. However, alongside extended survival, maintaining quality of life (QoL) and enabling patients to return to everyday life have become equally vital goals. Entinostat, a novel histone deacetylase inhibitor (HDACi), stands out with its well-tolerated safety profile and convenient dosing regimen. By enhancing both survival and QoL, it provides new therapeutic possibilities for HR⁺ breast cancer patients. Dr. Jun Cao from Fudan University Shanghai Cancer Center shares insights into managing QoL in the chronic disease era and highlights the clinical advantages of entinostat.
Advancing Liver Cancer Treatment: A Cross-Border Dialogue with Dr. Qin Shukui and Dr. Pablo Sarobe

Advancing Liver Cancer Treatment: A Cross-Border Dialogue with Dr. Qin Shukui and Dr. Pablo Sarobe

Liver cancer remains one of the deadliest malignancies worldwide, with China carrying a significant burden of cases. Understanding the unique epidemiology, molecular characteristics, and treatment strategies across different regions is crucial for advancing patient outcomes. In an exclusive cross-border dialogue, Professor Qin Shukui of Nanjing Tianyin Mountain Hospital, China, and Professor Pablo Sarobe of the University of Navarra Medical School, Spain, share their insights into the latest breakthroughs in liver cancer treatment. They discuss the evolving role of immunotherapy, targeted therapy, and the importance of global collaboration in shaping the future of liver cancer care. Watch the full conversation to gain expert perspectives on emerging treatment strategies, biomarker-driven approaches, and the future of liver cancer therapy.
EASL Liver Cancer Summit | Professor Abdel Ghani Atef: FibroScan Aids in Early Screening of Liver Cancer

EASL Liver Cancer Summit | Professor Abdel Ghani Atef: FibroScan Aids in Early Screening of Liver Cancer

Hepatocellular carcinoma (HCC), the most common primary malignant liver tumor, is one of the leading causes of death in patients with cirrhosis. Non-invasive diagnostic tools such as transient elastography (FibroScan) have shown great promise in identifying patients at high risk of HCC. Recently, the 2025 EASL Liver Cancer Summit was held in Paris, France. Professor Abdel Ghani Atef from the Damas Liver & G.I.T Center in Egypt presented research on the value of ultrasound elastography in the early detection of HCC in patients with cirrhosis. To this end, a journalist from Oncology Frontier traveled to the summit and invited Professor Abdel Ghani Atef to have an in-depth discussion on topics such as the role of FibroScan in HCC screening and the significance of liver stiffness measurement cutoff values.
News of ASH：Overview of Acute Myeloid Leukemia Research Advances in 2024

News of ASH：Overview of Acute Myeloid Leukemia Research Advances in 2024

The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, gathering over 30,000 experts and scholars from around the world. This year’s conference featured numerous carefully curated sessions, providing profound insights into fundamental research, innovative therapies, and disease management in hematology. To highlight the key findings from ASH 2024, Hematology Frontier presents the News of ASH series, offering a concise summary of the latest breakthroughs in the field.